B Riley has initiated Centessa Pharmaceuticals (NASDAQ:CNTA) with a buy rating citing the potential of the company's orexin 2 receptor agonists for sleep disorders. The firm has a $33 price target (~...
Source LinkB Riley has initiated Centessa Pharmaceuticals (NASDAQ:CNTA) with a buy rating citing the potential of the company's orexin 2 receptor agonists for sleep disorders. The firm has a $33 price target (~...
Source Link
Comments